Q-linea ABOMXSTO: QLINEA

Q-linea appoints Malin Svensson as new Chief Financial Officer

· Issued by Q-linea AB

Summary by 6ix AI

Q-linea AB (publ), an infection diagnostics company, has appointed Malin Svensson as Chief Financial Officer and Investor Relations manager. She will take up the position no later than January 1, 2027.

Key details

  • Malin Svensson currently serves as VP Finance of Pricer AB, has held senior finance and leadership roles in listed and international companies, and holds a degree in Business Administration and Economics.
  • Annika Blondeau Henriksson is currently Interim CFO of Q-linea AB.

6ix AI wrote this summary from the release below and checked it against the release.

Q-linea AB (publ) today announces that Malin Svensson has been appointed Chief Financial Officer and Investor Relations manager. She will assume her position no later than January 1, 2027

Malin Svensson brings extensive experience from senior finance and leadership roles in listed and international companies. She currently serves as VP Finance of Pricer AB and holds a degree in Business Administration and Economics.

"I am very pleased to welcome Malin to Q-linea. Her broad financial experience, leadership background and strong drive will contribute to our team as we accelerate our growth journey through 2027 and beyond. I welcome Malin to the management team", says Stuart Gander, President and CEO of Q-linea.

For more information, please contact:


Stuart Gander, President & CEO, Q-linea
[email protected]

Annika Blondeau Henriksson, Interim CFO, Q-linea AB
[email protected]
+ 46 (0) 70-600 15 20

About Q-linea


Q-linea AB (publ) is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company's core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.
Q-linea’s flagship technology, ASTar®, is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea AB is listed on Nasdaq Stockholm (STO:QLINEA).

Attachments


Q-linea appoints Malin Svensson as new Chief Financial Officer

© Modular Finance, source Nordic Press Releases

Q-linea AB on 6ix

Earlier from Q-linea

All Q-linea news releases